哈密霉菌性阴道炎怎么治疗好哈密上环多久要取环,哈密怎样做可以提高性能力,哈密市博爱女子医院好不好,哈密口碑好的不要孩子医院,哈密早孕试纸两道杠都很深,哈密包皮割的大概费用,哈密宫颈糜烂度治疗

BEIJING, Sept. 24 (Xinhuanet) -- The city government called on residents to register their dogs on time and keep better control of them to fight the increasing number of rabies cases during a discussion of the Beijing Municipal People's Congress on Friday."As the number of dogs in the city rises, the number of dog bites is also going up," said Lei Decai, director of the rural affairs committee of the people's congress.Last year, more than 30,000 residents were bitten by dogs and nine died of rabies. As of June this year, six people have died of rabies, Lei said."The main problem lies in the registration of dogs," he said, adding that the number of unlicensed dogs in the city is unknown. A man takes his dog for a spin on the back of a motorized tricycle in a Beijing street last month. The city plans to strengthen management of dogs in the future in an effort to combat the spread of rabies, which can be fatal if it is not treated in timeAt the beginning of June, eight residents were attacked by dogs in Beijing's Olympic Forest Park.One of them, Zhao Haiyan, 56, a retiree, was bitten in her left leg as she walked in the park. The puncture wounds left her leg bleeding."An officer in the park brought me to a hospital to get vaccinated for rabies, and I had no idea who I could ask for compensation, because the dog was fed by workers in a construction site and had no registration," she told China Daily."Now I worry when I see an unleashed dog," she added.Zhao is not alone. Cao Lifang, also 56, has helped a friend care for a dog since February. Dabai, a 6-year-old male Samoyed, bit her in mid-June when she was trying to keep him from fighting another dog.The attack left a deep bite mark on Cao's left hand, and she had to take anti-rabies injections for more than a month.

CHENGDU, Sept. 3 (Xinhua) -- A list of this year's top 500 Chinese enterprises was unveiled in the city of Chengdu in southwest China's Sichuan Province on Saturday.The Sinopec Group was ranked first, with last year's revenues reaching 1.97 trillion yuan (307.81 billion U.S. dollars), followed by the China National Petroleum Corp. and State Grid Corp., whose revenues hit 1.72 trillion yuan and 1.53 trillion yuan last year, respectively.The rest of the top 10 was rounded out by the Industrial and Commercial Bank of China, China Mobile, China Railway Group, China Railway Construction Corp., China Construction Bank, China Life Insurance Co. and Agricultural Bank of China.The list is the 10th of its kind to be jointly released by the China Enterprise Confederation and the China Enterprise Directors Association. The threshold for entering the list was raised to 14.2 billion yuan in revenues, an increase over the 11.08-billion-yuan threshold used during the previous year.Revenues for China's top 500 companies rose 31.6 percent year-on-year to 36.31 trillion yuan in 2010, while their total assets increased by 18.4 percent to 108.1 trillion yuan, the two organizations said.The companies reported profits of 2.08 trillion yuan for last year, a rise of 38.67 percent from one year earlier.They paid 2.73 trillion yuan in taxes in 2010, accounting for 37.3 percent of the country's total tax revenues.

BEIJING, June 10 (Xinhua) -- The nation's drug watchdog on Friday publicized a draft national standard of sulfur dioxide residue in Chinese herbal medicine, which is open for public opinion until Sept. 9 this year.The maximum amount of sulfur dioxide residue is 400 mg in one kg of each of 11 specified kinds of herbal medicine, such as Chinese yams, Gastrodia elata and Codonopsis pilosola, according to the draft standard unveiled by the State Food and Drug Administration (SFDA).The standard provides a 150-mg-per-kg limit for all other kinds of herbal medicine.Fumigation with sulfur is used as a way of drying some herbal medicine by growers, and currently have no alternative that is both cheap and convenient.The SFDA said it doesn't favor the drying herbal medicine through fumigation with sulfur and urges research efforts to invent new alternatives.According to the World Health Organization, the tolerable maximum amount of sulfur dioxide that a human body can take in one day is 0.7 mg per kg, which means that an adult of 60 kg should not take in more than 42 mg of sulfur dioxide a day.Long-term exposure to high amounts of sulfur dioxide can cause damage to human body, especially the respiratory system, according to experts. 

SAN FRANCISCO, Sept. 9 (Xinhua) -- AOL's chief executive officer (CEO) Tim Armstrong has reached out to Yahoo for talks of a merger of the two companies, U.S. media reported on Friday.Armstrong is discussing options for a combination aimed at strengthening the two Internet companies, Bloomberg quoted two people who are familiar with the matter as saying.The report said that the AOL CEO had been interested in a merger with Yahoo last year but was rejected while Carol Bartz served as Yahoo CEO, who was ousted by Yahoo's board on Tuesday.Reconsidering the option after Bartz's departure, Armstrong has talked with private equity firms and investment bankers from Allen & Co. working with Yahoo.Under one scenario being considered, Yahoo would acquire AOL and Armstrong would become CEO of the combined company, said the source.Both Yahoo and AOL are suffering from declining revenues, struggling to compete against companies like Google and Facebook. Some analysts said that the merger could not provide a long-term solution to the problems the two companies face after they failed to keep up with Internet trends.

BEIJING, August 4 (Xinhuanet) -- Medtronic Inc. is giving Yale University a 2.5 million U.S. dollar grant to review the safety and effectiveness of its controversial spine treatment called Infuse Bone Graft, according to The Wall Street Journals Thursday.Under terms of the pact, the company will release to Yale and eventually the public what participants described as an unprecedented amount of clinical trial and other data. The university will select two research teams from other organizations to perform separate analyses of the data.The announcement comes in the wake of a paper in June in the Spine Journal. The paper revealed that several clinical studies of Infuse, conducted by surgeons with strong economic ties to Medtronic, failed to report serious complications that arose in the trials. The critical paper also found that many of the studies were designed in ways in favor of Infuse over a treatment given to a control group.Medtronic disputes some of the findings and is conducting an internal investigation of the matter.Infuse accounts for about 700 million dollars in annual sales for Medtronic. The product is under investigation by the Senate Finance Committee over the role payments to physicians who may have played how studies were reported.